Skip to main content
Midas Edge

PLIANT THERAPEUTICS INC

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

PLRX$0.80-1.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Stockholders’ Equity

AdditionalPaid-InCapital · AccumulatedOtherComprehensive(Loss) Gain · AccumulatedDeficit · TotalStockholders'Equity
Common Stock
Shares · Amount
Balance at December 31, 202136,083,301$3$414,348$(201)$(215,091)$199,059
Common stock issued in a public offering, net of offering expenses12,432,4322215,399——215,401
Issuance of common stock under benefit plans403,680—1,360——1,360
Vesting of restricted stock awards21,841—2——2
Stock-based compensation expense——22,598——22,598
Net unrealized loss on short-term investments———(1,757)—(1,757)
Net loss————(123,321)(123,321)
Balance at December 31, 202248,941,254$5$653,707$(1,958)$(338,412)$313,342
Common stock issued in a public offering, net of offering expenses9,583,3341269,781——269,782
Issuance of common stock under benefit plans1,396,414—5,002——5,002
Stock-based compensation expense——44,483——44,483
Net unrealized gain on short-term investments———2,303—2,303
Net loss————(161,336)(161,336)
Balance at December 31, 202359,921,002$6$972,973$345$(499,748)$473,576
Issuance of common stock under benefit plans939,836—3,207——3,207
Stock-based compensation expense——37,626——37,626
Net unrealized loss on short-term investments———(24)—(24)
Net loss————(210,304)(210,304)
Balance at December 31, 202460,860,838$6$1,013,806$321$(710,052)$304,081
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.